SPECIALTY GUIDELINE MANAGEMENT

ZYNTEGLO (betibeglogene autotemcel)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Zynteglo is indicated for the treatment of adult and pediatric patients with beta-thalassemia who require regular blood cell (RBC) transfusions.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

- A. Molecular or genetic testing results documenting transfusion-dependent beta-thalassemia genotype
- B. Chart notes or medical record documenting history of blood cell transfusions for the previous two years

III. PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a hematologist.

IV. CRITERIA FOR INITIAL APPROVAL

Beta-thalassemia

Authorization of 3 months for a one-time administration may be granted when all of the following criteria are met:

- A. Member is 4 years of age or older and meets both of the following criteria:
 - 1. Member weighs at least 6 kg
 - 2. Member is reasonably anticipated to provide at least the minimum number of cells required to initiate the manufacturing process
- B. Member has a diagnosis of transfusion-dependent beta-thalassemia with a non- β 0/ β 0 OR β 0/ β 0 genotype confirmed via genetic testing (Appendix A)
- C. Member requires regular blood cell transfusions and meets one of the following criteria within the previous two years:
 - 1. Member has received at least 100 milliliter per kilogram of packed red blood cells (pRBCs) per year
 - 2. Member has received at least 8 transfusions events of packed red blood cells (pRBCs) per year
- D. Member is eligible for a hematopoietic stem cell transplant (HSCT) but is unable to find a matched related donor
- E. Member has not received prior hematopoietic stem cell transplant (HSCT)
- F. Member has not received Zynteglo or any other gene therapy previously

Zynteglo 5544-A SGM P2023.docx

© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



- G. Member does not have any of the following conditions:
 - 1. Positive for the presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2), hepatitis B virus (HBV), or hepatitis C (HCV)
 - 2. Any prior or current malignancy
 - 3. Advanced liver disease (e.g., bridging fibrosis, cirrhosis, active hepatitis)
 - 4. Severely elevated iron in the heart (i.e., patients with cardiac T2* less than 10 msec by MRI)


V. APPENDIX

Examples of non-β0/β0 OR β0/β0 genotypes:

- 1. β0/β0
- 2. $\beta 0/\beta +$
- 3. BE/B0
- 4. β0/IVS-I-110
- 5. IVS-I-110/IVS-1-110

VI. REFERENCES

- 1. Zynteglo [package insert]. Somerville, MA: Bluebird Bio; August 2022.
- 2. Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia. N Engl J Med. 2022;386(5):415-427.
- 3. Ashutosh Lal, Franco Locatelli, Janet L. Kwiatkowski, Andreas E. Kulozik, Evangelia Yannaki, John B. Porter, Isabelle Thuret, Martin G. Sauer, Heidi Elliot, Ying Chen, Richard A. Colvin, Alexis A. Thompson; Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Either a β0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene. Blood 2019; 134 (Supplement 1): 815.
- 4. Cappellini MD, Farmakis D, Porter J, Taher A. 2021 Guidelines for the management of transfusion dependent thalassaemia (TDT). Nicosia, Cyprus: Thalassaemia International Federation, 2021.



© 2023 CVS Caremark. All rights reserved.



2

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of

pharmaceutical manufacturers that are not affiliated with CVS Caremark.